In an amicus brief filed with the United States Supreme Court, AAM explained that the Federal Circuit had misinterpreted the law governing where Hatch-Waxman patent lawsuits can be filed resulting in an imbalance that favored the brand industry and delayed patient access to lower-cost generic drugs. On May 22, 2017, the Supreme Court agreed with AAM and overturned the Federal Circuit’s ruling.
Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27